Oxford Vacmedix ROP technology presented at 2018 Myongji International Cancer Symposium
June 2018 – Oxford Vacmedix ROP technology presented at 2018 Myongji International Cancer Symposium View in PDF
Company News
Oxford Vacmedix completes Series A financing
Oxford Vacmedix UK Limited (OVM) has completed its Series A financing round of $12.5m (£9m). Oxford Vacmedix UK Limited (OVM), a UK-based biopharma company focused on the development of cancer vaccines, has completed its Series A financing round of $12.5m (£9m) with a consortium of South Korean and Chinese investors, including Cancer ROP, a leading …